EyePoint Pharmaceuticals, Inc. (EYPT) News

EyePoint Pharmaceuticals, Inc. (EYPT): $9.36

1.18 (-11.20%)

POWR Rating

Component Grades

Momentum

C

Stability

F

Sentiment

Quality

C

Filter EYPT News Items

EYPT News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

EYPT News Highlights

  • For EYPT, its 30 day story count is now at 13.
  • Over the past 15 days, the trend for EYPT's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • DEC, TOP and AGE are the most mentioned tickers in articles about EYPT.

Latest EYPT News From Around the Web

Below are the latest news stories about EYEPOINT PHARMACEUTICALS INC that investors may wish to consider to help them evaluate EYPT as an investment opportunity.

EyePoint Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

WATERTOWN, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint Pharmaceuticals will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10, 2024 at 10:30 a.m. PT/1:30 p.m. ET. A webcast and subs

Yahoo | December 20, 2023

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregat

Yahoo | December 18, 2023

What EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) 194% Share Price Gain Is Not Telling You

EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) shareholders would be excited to see that the share price has had a...

Yahoo | December 18, 2023

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Analysts Just Trimmed Their Revenue Forecasts By 11%

Market forces rained on the parade of EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) shareholders today, when the...

Yahoo | December 13, 2023

EyePoint Pharmaceuticals (EYPT) is a Great Momentum Stock: Should You Buy?

Does EyePoint Pharmaceuticals (EYPT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Yahoo | December 11, 2023

Institutional investors have a lot riding on EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) with 43% ownership

Key Insights Institutions' substantial holdings in EyePoint Pharmaceuticals implies that they have significant...

Yahoo | December 11, 2023

EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares

WATERTOWN, Mass., Dec. 08, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced the closing of its previously announced underwritten public offering of 13,529,411 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase an additional 1,764,705 shares of common stock, at the publ

Yahoo | December 8, 2023

Wall Street Analysts Believe EyePoint Pharmaceuticals (EYPT) Could Rally 77.05%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 77.1% in EyePoint Pharmaceuticals (EYPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Yahoo | December 8, 2023

What Makes EyePoint Pharmaceuticals (EYPT) a Good Fit for 'Trend Investing'

If you are looking for stocks that are well positioned to maintain their recent uptrend, EyePoint Pharmaceuticals (EYPT) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Yahoo | December 8, 2023

Insider Sell Alert: Chief Corp Dev. & Strat. ...

EyePoint Pharmaceuticals Inc (NASDAQ:EYPT), a specialty pharmaceutical company committed to developing and commercializing therapies for eye diseases, has recently witnessed a significant insider sell by one of its top executives.

Yahoo | December 7, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!